Pricing pressure in the US to weigh on Dr Reddy’s Q2

SENSEX 73,249.39

 -460.30

NIFTY 22,687.65

 -123.70

CRUDEOIL 9,397.00

+ 189.00

GOLD 143,888.00

 -2,191.00

SILVER 201,138.00

 -8,030.00

SENSEX 73,249.39

 -460.30

NIFTY 22,687.65

 -123.70

NIFTY 22,687.65

 -123.70

CRUDEOIL 9,397.00

+ 189.00

CRUDEOIL 9,397.00

+ 189.00

GOLD 143,888.00

 -2,191.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

The drug maker, expected to report results on October 23, could post sequential improvements in revenue and profitability

By BL Hyderabad Bureau

Updated - October 22, 2026 at 08:59 PM.

Steady growth in the domestic market in recent quarters is also expected to support the company’s overall performance.

Pharma major Dr Reddy’s Laboratories is expected to have faced continued pricing pressure in the US market, which could have weighed on its margins in the second quarter of the current financial year, ended September.

The Hyderabad-based company is scheduled to announce its Q2 FY27 results on October 23 (Friday).

Despite pricing pressure in the US and continued increases in logistics expenses driven by geopolitical factors affecting some markets, the drug maker is expected to report sequential improvements in revenue and profitability, though its EBITDA margin is likely to remain below 20 per cent.

Steady growth in the domestic market in recent quarters is also expected to support the company’s overall performance.

In Q2 FY26, the company had posted a consolidated net profit of ₹1,437 crore against revenues of ₹8,805 crore.

Published on October 22, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers